ReviewBiomedicines2026
Recent Advances in the Diagnosis and Management of Clinically Significant Portal Hypertension in Liver Cirrhosis: A Clinical Review.
Review in Biomedicines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clinically significant portal hypertension (CSPH) is a key driver of decompensation events and complications in patients with liver cirrhosis. The manifestation of hepatic decompensation is, in turn, associated with a drastic deterioration in prognosis in this vulnerable population. Therefore, a timely identification of patients at risk as well as an optimal drug treatment are key elements in the therapeutic management of patients with cirrhosis to improve survival. While invasive measurements represent the gold standard for assessing portal hypertension, significant progress has been made in recent years in developing non-invasive methods for evaluating CSPH, including the NICER and the ANTICIPATE model. These models, combining variables such as liver and spleen stiffness in combination with biomarkers such as platelet count for risk prediction, reliably identify patients with CSPH who are at risk for hepatic decompensation. In addition to advances in diagnostics, new evidence has emerged regarding optimal drug management strategies. Non-selective beta blockers are an important treatment option, even though a certain proportion of patients respond inadequately. Therefore, updated strategies are needed to identify these non-responders and improve treatment effectiveness. This review article provides a comprehensive overview of modern diagnostic approaches for CSPH, describes current management strategies including updated approaches, and provides an outlook on emerging potential treatment options.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.